RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Renalytix plc
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026
- Market cap
- $375.75M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$166.76 (−97.91%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Renalytix plc saw revenue fall 18.7% to $2.35M over the twelve months to Sep 30, 2024.
Revenue
$2.35M
-18.7% vs. a year earlier
Operating income
-$24.81M
TTM Q1 2025
EPS, diluted
-$0.26
TTM Q1 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2024
Valuation
- Market cap
- $375.75M
- P/E ratio
- –
- Price to sales
- 159.76
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.35M
- Net income
- -$28.03M
- EPS, diluted
- -$0.26
- Book value per share
- -$0.11
- Diluted shares
- 106M
Seven years at a glance
Fiscal years 2018 to 2024 and trailing twelve months, USD
Revenue
$2.35M-18.7% YoY
Gross profit
$299.00K-26.0% YoY
Operating income
-$24.81M
Net income
-$28.03M
EPS, diluted
-$0.26
Free cash flow
–
Reported periodTrailing twelve months